New York, New York (PRWEB) December 09, 2011
Parker Waichman Alonso LLP urges the U.S. Food & Drug Administration (FDA) to accept the recommendation of its outside advisors to update the labels for Yaz, Yasmin and other birth control pills containing the synthetic progestin, drospirenone, with information highlighting recent data indicating they pose a higher risk of dangerous, and potentially fatal, blood clots compared to other oral contraceptives. During a joint meeting of the FDA's Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee convened on December 8, members of the committees voted 21-5 that the current information contained on the drugs’ labels regarding blood clot risks is inadequate and should be updated.
“We are heartened by the conclusions of the Committee,” stated Andres F. Alonso, a partner with Parker Waichman Alonso, “and hope that the manufacturers of these products will immediately update the prescribing information to adequately disclose the true risks associated with their use.”
The Committees' vote comes as evidence continues to mount indicating that Yaz, Yasmin and similar oral contraceptives are more likely to cause life-threatening blood clots compared to older types of birth control pills. Recently, Newsinferno.com reported that a study commissioned by the FDA and released just last month found that women who use drospirenone pills were 75 percent more likely to experience clots compared to those taking other oral contraceptives. The FDA-funded study involved the medical histories of more than 800,000 American women, all of whom were on some type of birth control between 2001 and 2008.
According to the Associated Press, since 2009 a total of five large studies have found evidence that drospirenone birth control pills pose a higher risk of blood clots compared to those containing an older form of progestin. Only two large studies, both funded by the makers of Yaz and Yasmin, have failed to find a higher risk.
Blood clots can trigger heart attacks, strokes and blockages in lungs or blood vessels, so even a slightly increased risk can have serious consequences for young women taking Yaz, Yasmin and other drospirenone-containing birth control pills. In light of this public health threat, Parker Waichman Alonso LLP urges the FDA to adopt the recommendation of its outside advisors, and order Bayer to add stronger blood clot warnings to the labels of Yaz and Yasmin immediately.
More than 10,000 lawsuits have been filed against Bayer Healthcare Pharmaceuticals, Inc., Bayer Pharma AG, and other makers of drospirenone-containing birth control pills by women who claim to have suffered strokes, pulmonary emboli, deep vein thrombosis, blood clots, gallbladder disease, and other serious injuries after taking these medications. Over 7,000 such lawsuits have been consolidated in the Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100) currently pending before the Honorable Judge David R. Herndon in the United States District Court for the Southern District of Illinois. Mr. Alonso is serving as a member of the Plaintiffs Steering Committee in that litigation.
Parker Waichman Alonso LLP continues to offer free legal evaluations to victims of drospirenone contraceptives, including Yaz and Yasmin. If you or a loved one suffered a heart attack, blood clot or stroke while taking one of these birth control pills, please visit the firm's Yaz and Yasmin injury page at http://www.yourlawyer.com.
For more information regarding Yaz and Yasmin lawsuits and Parker Waichman Alonso LLP, please visit: http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Contact: Parker Waichman Alonso LLP